Literature DB >> 32669941

Management of chronic lymphocytic leukemia in Canada during the coronavirus pandemic.

L H Sehn1, P Kuruvilla2, A Christofides3, J Stakiw4.   

Abstract

The emergence of the covid-19 disease pandemic caused by the 2019 novel coronavirus has required a re-evaluation of treatment practices for clinicians caring for patients with chronic lymphocytic leukemia (cll). The American Society for Hematology (ash) has provided a series of recommendations for the treatment of patients with cll during the pandemic, covering a range of topics, including testing for covid-19, cll treatment initiation and selection, use of immunoglobulin therapy, in-person monitoring, and treatment of patients with cll and covid-19. We summarize the ash recommendations and discuss their applicability as guidelines for the treatment of cll during the covid-19 pandemic in Canada. 2020 Multimed Inc.

Entities:  

Keywords:  Coronavirus; chronic lymphocytic leukemia; covid-19

Mesh:

Substances:

Year:  2020        PMID: 32669941      PMCID: PMC7339858          DOI: 10.3747/co.27.6769

Source DB:  PubMed          Journal:  Curr Oncol        ISSN: 1198-0052            Impact factor:   3.677


  7 in total

1.  Analysis of the risk of infection in patients with chronic lymphocytic leukemia in the era of novel therapies.

Authors:  AnnaLynn M Williams; Andrea M Baran; Philip J Meacham; Megan M Feldman; Hugo E Valencia; Catherine Newsom-Stewart; Nealansh Gupta; Michelle C Janelsins; Paul M Barr; Clive S Zent
Journal:  Leuk Lymphoma       Date:  2017-07-11

Review 2.  A Canadian perspective on the use of immunoglobulin therapy to reduce infectious complications in chronic lymphocytic leukemia.

Authors:  S Lachance; A L Christofides; J K Lee; L H Sehn; B C Ritchie; C Shustik; D A Stewart; C L Toze; E Haddad; D C Vinh
Journal:  Curr Oncol       Date:  2016-02-18       Impact factor: 3.677

Review 3.  Antibody deficiency secondary to chronic lymphocytic leukemia: Should patients be treated with prophylactic replacement immunoglobulin?

Authors:  Fatima Dhalla; Mary Lucas; Anna Schuh; Malini Bhole; Rashmi Jain; Smita Y Patel; Siraj Misbah; Helen Chapel
Journal:  J Clin Immunol       Date:  2014-02-21       Impact factor: 8.317

Review 4.  The immunodeficiency of chronic lymphocytic leukaemia.

Authors:  A D Hamblin; T J Hamblin
Journal:  Br Med Bull       Date:  2008-08-27       Impact factor: 4.291

5.  ILROG emergency guidelines for radiation therapy of hematological malignancies during the COVID-19 pandemic.

Authors:  Joachim Yahalom; Bouthaina Shbib Dabaja; Umberto Ricardi; Andrea Ng; N George Mikhaeel; Ivan R Vogelius; Tim Illidge; Shunan Qi; Andrew Wirth; Lena Specht
Journal:  Blood       Date:  2020-05-21       Impact factor: 22.113

6.  Balancing risk and benefit during coronavirus.

Authors:  Laurie H Sehn
Journal:  Blood       Date:  2020-05-21       Impact factor: 22.113

7.  The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients.

Authors:  Steven P Treon; Jorge J Castillo; Alan P Skarbnik; Jacob D Soumerai; Irene M Ghobrial; Maria Luisa Guerrera; Kirsten Meid; Guang Yang
Journal:  Blood       Date:  2020-05-21       Impact factor: 22.113

  7 in total
  3 in total

Review 1.  Managing the Risk of Infection in Chronic Lymphocytic Leukemia in the Era of New Therapies.

Authors:  Daniel Rivera; Alessandra Ferrajoli
Journal:  Curr Oncol Rep       Date:  2022-04-02       Impact factor: 5.945

Review 2.  Management of patients with chronic lymphocytic leukemia during the SARS-CoV-2 pandemic.

Authors:  Romeo Gabriel Mihaila
Journal:  Oncol Lett       Date:  2021-07-03       Impact factor: 2.967

3.  Venetoclax-Rituximab Treatment of Relapsed/Refractory CLL During the COVID-19 Pandemic: A Real-Life Experience in Selected Central-Southern Italian Regions.

Authors:  Stefano Molica; Paolo Sportoletti; Nicola Di Renzo; Pellegrino Musto; Fabrizio Pane; Francesco Di Raimondo
Journal:  Mediterr J Hematol Infect Dis       Date:  2021-07-01       Impact factor: 2.576

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.